NASDAQ: THTX
Theratechnologies Inc Stock

$2.84-0.03 (-1.05%)
Updated Apr 30, 2025
THTX Price
$2.84
Fair Value Price
N/A
Market Cap
$130.58M
52 Week Low
$1.08
52 Week High
$3.13
P/E
-50.71x
P/B
-7.63x
P/S
1.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$62.00M
Earnings
-$2.61M
Gross Margin
79%
Operating Margin
15.51%
Profit Margin
-4.2%
Debt to Equity
-3.31
Operating Cash Flow
-$4M
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

THTX Overview

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine THTX's potential to beat the market

BBuy
  • Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
THTX
Ranked
#22 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important THTX news, forecast changes, insider trades & much more!

THTX News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how THTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

THTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
THTX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
THTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more THTX due diligence checks available for Premium users.

Valuation

THTX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-50.71x
Industry
-162.28x
Market
29.18x

THTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-7.63x
Industry
4.45x

THTX's financial health

Profit margin

Revenue
$13.4M
Net Income
$82.4k
Profit Margin
0.6%
THTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
THTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$39.8M
Liabilities
$57.0M
Debt to equity
-3.31
THTX's short-term assets ($26.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
THTX's long-term liabilities ($32.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
THTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
THTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.9M
Investing
-$4.9M
Financing
$3.3M
THTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

THTX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
THTXB$130.58M-0.87%-50.71x-7.63x
LXEOF$130.46M+10.08%-1.27x1.12x
ENTAC$129.92M+5.18%-1.23x1.16x
TARAC$128.69M+2.94%-1.61x0.77x
SCPHD$128.22M+7.59%-1.34x9.63x

Theratechnologies Stock FAQ

What is Theratechnologies's quote symbol?

(NASDAQ: THTX) Theratechnologies trades on the NASDAQ under the ticker symbol THTX. Theratechnologies stock quotes can also be displayed as NASDAQ: THTX.

If you're new to stock investing, here's how to buy Theratechnologies stock.

What is the 52 week high and low for Theratechnologies (NASDAQ: THTX)?

(NASDAQ: THTX) Theratechnologies's 52-week high was $3.13, and its 52-week low was $1.08. It is currently -9.27% from its 52-week high and 162.96% from its 52-week low.

How much is Theratechnologies stock worth today?

(NASDAQ: THTX) Theratechnologies currently has 45,980,019 outstanding shares. With Theratechnologies stock trading at $2.84 per share, the total value of Theratechnologies stock (market capitalization) is $130.58M.

Theratechnologies stock was originally listed at a price of $19.00 in Jun 16, 2011. If you had invested in Theratechnologies stock at $19.00, your return over the last 13 years would have been -85.05%, for an annualized return of -13.6% (not including any dividends or dividend reinvestments).

How much is Theratechnologies's stock price per share?

(NASDAQ: THTX) Theratechnologies stock price per share is $2.84 today (as of Apr 30, 2025).

What is Theratechnologies's Market Cap?

(NASDAQ: THTX) Theratechnologies's market cap is $130.58M, as of May 2, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Theratechnologies's market cap is calculated by multiplying THTX's current stock price of $2.84 by THTX's total outstanding shares of 45,980,019.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.